Vascular endothelial growth factor (VEGF) and its effect on angiogenesis - PubMed (original) (raw)
Review
. 2000 Sep-Oct;6(5):1047-52.
Affiliations
- PMID: 11208453
Review
Vascular endothelial growth factor (VEGF) and its effect on angiogenesis
J Jośko et al. Med Sci Monit. 2000 Sep-Oct.
Abstract
The article discusses the role of vascular endothelial growth factor(VEGF) in angiogenesis in embryonic development, particularly the effect of VEGF on capillary formation in response to chronic tissue ischemia and hypoxia. The sources and action of numerous angiogenic and angiostatic factors responsible for morphologic development of endothelial cells and disturbances in VEGF and FGF secretion are also presented. Increased VEGF and VEGF receptor expression enhances vascular permeability and angiogenesis, and is the cause of tissue edema as well as tumor and metastasis formation. VEGF appears to have a beneficial effect only in ischemic diseases of the heart and peripheral vessels. The article highlights the therapeutic implication of VEGF suppression in other areas of ischemia.
Similar articles
- Functions of the VEGF/VEGF receptor system in the vascular system.
Breier G. Breier G. Semin Thromb Hemost. 2000;26(5):553-9. doi: 10.1055/s-2000-13212. Semin Thromb Hemost. 2000. PMID: 11129412 Review. - Angiogenesis in embryos and ischemic diseases.
Breier G, Damert A, Plate KH, Risau W. Breier G, et al. Thromb Haemost. 1997 Jul;78(1):678-83. Thromb Haemost. 1997. PMID: 9198238 Review. - VEGFs, receptors and angiogenesis.
Veikkola T, Alitalo K. Veikkola T, et al. Semin Cancer Biol. 1999 Jun;9(3):211-20. doi: 10.1006/scbi.1998.0091. Semin Cancer Biol. 1999. PMID: 10343072 Review. - Lymphatic versus blood vascular endothelial growth factors and receptors in humans.
Partanen TA, Paavonen K. Partanen TA, et al. Microsc Res Tech. 2001 Oct 15;55(2):108-21. doi: 10.1002/jemt.1162. Microsc Res Tech. 2001. PMID: 11596156 Review. - Regulation of angiogenesis via vascular endothelial growth factor receptors.
Veikkola T, Karkkainen M, Claesson-Welsh L, Alitalo K. Veikkola T, et al. Cancer Res. 2000 Jan 15;60(2):203-12. Cancer Res. 2000. PMID: 10667560 Review. No abstract available.
Cited by
- Hypoxia-inducible factors as molecular targets for liver diseases.
Ju C, Colgan SP, Eltzschig HK. Ju C, et al. J Mol Med (Berl). 2016 Jun;94(6):613-27. doi: 10.1007/s00109-016-1408-1. Epub 2016 Apr 20. J Mol Med (Berl). 2016. PMID: 27094811 Free PMC article. Review. - Cardiovascular gene therapy: current status and therapeutic potential.
Gaffney MM, Hynes SO, Barry F, O'Brien T. Gaffney MM, et al. Br J Pharmacol. 2007 Sep;152(2):175-88. doi: 10.1038/sj.bjp.0707315. Epub 2007 Jun 11. Br J Pharmacol. 2007. PMID: 17558439 Free PMC article. Review. - Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).
Cai YC, Zou Y, Ye YL, Sun HY, Su QG, Wang ZX, Zeng ZL, Xian LJ. Cai YC, et al. Invest New Drugs. 2011 Apr;29(2):300-11. doi: 10.1007/s10637-009-9366-x. Epub 2009 Dec 11. Invest New Drugs. 2011. PMID: 20012336 - Sexual dimorphism in gene expression after aneurysmal subarachnoid hemorrhage.
Friedrich V, Bi W, Sehba FA. Friedrich V, et al. Neurol Res. 2015;37(12):1054-9. doi: 10.1080/01616412.2015.1115211. Neurol Res. 2015. PMID: 26923576 Free PMC article. - HIF-1alpha: a valid therapeutic target for tumor therapy.
Hong SS, Lee H, Kim KW. Hong SS, et al. Cancer Res Treat. 2004 Dec;36(6):343-53. doi: 10.4143/crt.2004.36.6.343. Epub 2004 Dec 31. Cancer Res Treat. 2004. PMID: 20368827 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources